IGF::OT::IGF

代表美国国立卫生研究院16个研究所和中心的美国国立卫生研究院神经科学研究蓝图，宣布了一项神经治疗学大挑战，以解决神经系统疾病有效药物缺乏的问题。为了迎接这一重大挑战，NIH蓝图正在开创一种新的药物开发模式；一个将行业药物开发专业知识与美国国立卫生研究院资助研究的创新疾病生物学相结合的网络。蓝图神经治疗网络将作为虚拟制药公司运作

the NIH Blueprint for Neuroscience Research, representing sixteen NIH Institutes and Centers, announced a Grand Challenge for Neurotherapeutics to address the paucity of effective drugs for disorders of the nervous system. To meet this Grand Challenge, the NIH Blueprint is pioneering a new model for drug development; a network that integrates industry drug development expertise with the innovative disease biology that is the strength of NIH-funded research. The Blueprint Neurotherapeutics Network will operate as a virtual pharma Neuroscience researchers (principal investigators) with a compelling therapeutic rationale and starting materials for a drug development project will be matched with senior-level, industry-seasoned consultants who will design and direct the drug development plan. The principal investigators will conduct the bioactivity assays and biological work, and Contracted Research Organizations (CROs), which will be identified and funded by NIH through separate contracts, will implement all other drug development activities. The principal investigator, consultants, NIH staff, and CRO staff engaged in a project will constitute a Lead Development Team (LDT).